NCT05481463 is a Phase 2 clinical trial of Surufatinib in Pancreatic Neoplasms, sponsored by Sun Yat-sen University.

Who is sponsoring NCT05481463?

NCT05481463 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05481463?

Interventions in NCT05481463: Surufatinib, TAS-102.

What condition does NCT05481463 study?

NCT05481463 studies Pancreatic Neoplasms.

Is NCT05481463 still recruiting?

NCT05481463 is currently completed. Last updated 28 May 2025.

Last reviewed 2025-05-28 · How we verify

NCT05481463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Completed Phase 2 Last updated 28 May 2025

What this trial tests

Phase 2 trial testing Surufatinib in Pancreatic Neoplasms in 22 participants. Completed in 10 May 2025.

Timeline

30 January 2023

Primary endpoint
31 March 2025

10 May 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	30 January 2023
Primary completion	31 March 2025
Estimated completion	10 May 2025
Sites	1 location across China

Drugs / interventions tested

Surufatinib — full drug profile →
TAS-102

Conditions studied

Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749
Domestication and feedback: bidirectional hijacking in pancreatic ductal adenocarcinoma microenvironment.
Qiao Y, Yin H, Zhang Y, Zhang J, et al · · 2025 · cited 2× · PMID 40861469 · DOI 10.3389/fimmu.2025.1585858
Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.
Lu Y, Lin Q, Mo Y, Liu F, et al · · 2025 · PMID 41039600 · DOI 10.1186/s12943-025-02437-0

Verify or expand the search:

Other trials of Surufatinib

Trials testing the same drug.

NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors · Phase 2 · recruiting
NCT07086456 — Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal · Phase 2 · recruiting
NCT06531291 — Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Ne · Phase 2 · not yet recruiting

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

NCT07504471 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib · Phase 2 · recruiting
NCT07139236 — Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05481463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 28 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing